<DOC>
	<DOCNO>NCT02538185</DOCNO>
	<brief_summary>The study plan single-center , randomize , double-blind placebo-controlled , comparative Phase I , first-in-man study ass safety tolerability NanoJect™ device , immunogenicity rabies vaccine `` Vaccin rabique Pasteur® '' deliver NanoJect™ device ID route .</brief_summary>
	<brief_title>Intradermal Rabies Immunization Using NanoJect : A Comparative Study</brief_title>
	<detailed_description>This study enroll 66 volunteer randomly assign one three study arm . Each volunteer receive three injection three vaccination visit . Total study duration per volunteer 2 month .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Has complete write informed consent process . Is male female age 18 year 50 year . Agrees stay contact study site duration study , provide update contact information necessary , current plan move study area duration study . Agrees avoid elective surgery duration study . For female subject : agree avoid pregnancy duration study . Is good general health , confirm medical history , physical examination screen laboratory test . Oral body temperature 37.5 Celcius ( C ) . History evidence rabies vaccination rabies contact . Abnormal CBC ( Complete Blood Count ) laboratory value ( &gt; 10 % Upper Limit Normal ( ULN ) &gt; 10 % Lower Limit Normal ( LLN ) ) abnormal biochemistry value blood collect screening ( &gt; 10 % ULN &gt; 10 % LLN ) . Analysis repeat upon request clinician . History evidence autoimmune disease . History evidence past , present , future possible immunodeficiency state , include HIV 1 infection . History evidence chronic hepatitis , include presence antihepatitis B core antibody antihepatitis C antibodies.Participation investigational study study period . Received immunoglobulin blood product within 90 day prior study visit 2 . Received investigational drug therapy investigational vaccine within 180 day prior study . Received license vaccine within 45 day prior study visit 2 ( note : use license vaccine medically indicate study permit time ) . History evidence treatment , opinion investigator , may interfere vaccine response compromise safety subject . Received Chloroquin and/or Proguanil treatment within 420 day prior study . Use immunosuppressive drug anticoagulant . All female subject : currently pregnant lactating/nursing ; positive screening urine pregnancy test ; positive urine pregnancy test day study vaccination History evidence allergic disease reaction , opinion investigator , may compromise safety subject ( Notably : allergy active principle , excipients , polymyxin B , Streptomycin , Neomycin ) . History evidence dermatologic disease , opinion investigator , may interfere assessment injection site reaction . History evidence acute chronic disease , opinion investigator , may interfere evaluation safety immunogenicity vaccine compromise safety subject . Medical , psychiatric , occupational , substance abuse problem , opinion investigator , make unlikely subject comply protocol . History evidence brain disease , opinion investigator , may interfere vaccine compromise safety subject . Abnormal urinalysis screen visit , opinion investigator , clinically significant . Skin coloration ( skin color , tattoo , freckle ) , opinion investigator , could interfere injection reactogenicity assessment . Body Mass Index ( BMI ) &lt; = 18 = &gt; 33 ( weight/height2 ) . Immediate need rabies immunization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>